钠-葡萄糖转运蛋白2抑制剂的使用与糖尿病患者充气阴茎假体感染风险增加无关。

IF 2 3区 医学 Q2 UROLOGY & NEPHROLOGY
Eric Wahlstedt, Jessica Schardein, John Wahlstedt, Joshua J Horns, Vaibhavi Vichare, Rupam Das, Jim Hotaling, Kelli Gross
{"title":"钠-葡萄糖转运蛋白2抑制剂的使用与糖尿病患者充气阴茎假体感染风险增加无关。","authors":"Eric Wahlstedt, Jessica Schardein, John Wahlstedt, Joshua J Horns, Vaibhavi Vichare, Rupam Das, Jim Hotaling, Kelli Gross","doi":"10.1016/j.urology.2025.09.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine whether diabetic patients taking sodium-glucose transport protein 2 inhibitors (SGLT2i) are at increased risk of inflatable penile prosthesis (IPP) infections, given the association of SGLT2i with higher rates of urinary tract and genital infections, and to assess the frequency of IPP infections in this patient population.</p><p><strong>Materials and methods: </strong>We performed a retrospective review of all diabetic men who underwent IPP placement utilizing the IBM MarketScan insurance claims database between 2011-2021. Demographic data, including age, smoking status, and obesity, were obtained. An IPP infection was identified based on ICD-9/10 and CPT codes. Multivariable analyses were performed to assess the likelihood of IPP infections.</p><p><strong>Results: </strong>A total of 2838 patients were identified. The median age was 61 years (55-66 years), with 61.0% classified as obese and 18.9% identified as smokers. Among these patients, 883 (31.1%) were on an SGLT2i. At a median follow-up of 25 months (10-49 months), 82 (2.9%) patients developed an infection, including 28 (3.2%) patients on SGLT2i and 54 (2.8%) patients on other diabetes medications. SGLT2i use was associated with a nonsignificant increase in the hazard ratio (HR) for infection [1.26 (P = .39)], while obesity and smoking were associated with statistically significant HRs [2.02 (P = .02) and 2.20 (P < .01), respectively].</p><p><strong>Conclusion: </strong>SLGT2i likely does not have a large effect on rates of IPP infection and may be continued perioperatively. Smoking cessation and weight loss may decrease the risk of IPP infections in diabetic patients, and counseling on this should be considered.</p>","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sodium-Glucose Transport Protein 2 Inhibitor Use Is Not Associated With Increased Risk of Inflatable Penile Prosthesis Infections Among Diabetic Patients.\",\"authors\":\"Eric Wahlstedt, Jessica Schardein, John Wahlstedt, Joshua J Horns, Vaibhavi Vichare, Rupam Das, Jim Hotaling, Kelli Gross\",\"doi\":\"10.1016/j.urology.2025.09.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine whether diabetic patients taking sodium-glucose transport protein 2 inhibitors (SGLT2i) are at increased risk of inflatable penile prosthesis (IPP) infections, given the association of SGLT2i with higher rates of urinary tract and genital infections, and to assess the frequency of IPP infections in this patient population.</p><p><strong>Materials and methods: </strong>We performed a retrospective review of all diabetic men who underwent IPP placement utilizing the IBM MarketScan insurance claims database between 2011-2021. Demographic data, including age, smoking status, and obesity, were obtained. An IPP infection was identified based on ICD-9/10 and CPT codes. Multivariable analyses were performed to assess the likelihood of IPP infections.</p><p><strong>Results: </strong>A total of 2838 patients were identified. The median age was 61 years (55-66 years), with 61.0% classified as obese and 18.9% identified as smokers. Among these patients, 883 (31.1%) were on an SGLT2i. At a median follow-up of 25 months (10-49 months), 82 (2.9%) patients developed an infection, including 28 (3.2%) patients on SGLT2i and 54 (2.8%) patients on other diabetes medications. SGLT2i use was associated with a nonsignificant increase in the hazard ratio (HR) for infection [1.26 (P = .39)], while obesity and smoking were associated with statistically significant HRs [2.02 (P = .02) and 2.20 (P < .01), respectively].</p><p><strong>Conclusion: </strong>SLGT2i likely does not have a large effect on rates of IPP infection and may be continued perioperatively. Smoking cessation and weight loss may decrease the risk of IPP infections in diabetic patients, and counseling on this should be considered.</p>\",\"PeriodicalId\":23415,\"journal\":{\"name\":\"Urology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urology.2025.09.008\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urology.2025.09.008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:考虑到SGLT2i与尿路和生殖器感染的高发率相关,确定服用钠-葡萄糖转运蛋白2抑制剂(SGLT2i)的糖尿病患者发生充气阴茎假体(IPP)感染的风险是否增加,并评估该患者人群中IPP感染的频率。材料和方法:我们利用IBM MarketScan保险索赔数据库,对2011-2021年间接受IPP安置的所有糖尿病男性患者进行了回顾性研究。获得了人口统计数据,包括年龄、吸烟状况和肥胖。根据ICD-9/10和CPT编码鉴定IPP感染。进行多变量分析以评估IPP感染的可能性。结果:共发现2838例患者。中位年龄为61岁(55-66岁),61.0%为肥胖,18.9%为吸烟者。在这些患者中,883例(31.1%)接受SGLT2i治疗。在中位随访25个月(10-49个月)时,82例(2.9%)患者发生感染,包括28例(3.2%)使用SGLT2i的患者和54例(2.8%)使用其他糖尿病药物的患者。SGLT2i的使用与感染风险比(HR)的无统计学意义增加相关[1.26 (p=0.39)],而肥胖和吸烟与具有统计学意义的HR相关[2.02 (p=0.02)和2.20 (p)]。结论:SLGT2i可能对IPP感染率没有太大影响,可以继续围手术期使用。戒烟和减肥可降低糖尿病患者感染IPP的风险,应考虑就此进行咨询。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sodium-Glucose Transport Protein 2 Inhibitor Use Is Not Associated With Increased Risk of Inflatable Penile Prosthesis Infections Among Diabetic Patients.

Objective: To determine whether diabetic patients taking sodium-glucose transport protein 2 inhibitors (SGLT2i) are at increased risk of inflatable penile prosthesis (IPP) infections, given the association of SGLT2i with higher rates of urinary tract and genital infections, and to assess the frequency of IPP infections in this patient population.

Materials and methods: We performed a retrospective review of all diabetic men who underwent IPP placement utilizing the IBM MarketScan insurance claims database between 2011-2021. Demographic data, including age, smoking status, and obesity, were obtained. An IPP infection was identified based on ICD-9/10 and CPT codes. Multivariable analyses were performed to assess the likelihood of IPP infections.

Results: A total of 2838 patients were identified. The median age was 61 years (55-66 years), with 61.0% classified as obese and 18.9% identified as smokers. Among these patients, 883 (31.1%) were on an SGLT2i. At a median follow-up of 25 months (10-49 months), 82 (2.9%) patients developed an infection, including 28 (3.2%) patients on SGLT2i and 54 (2.8%) patients on other diabetes medications. SGLT2i use was associated with a nonsignificant increase in the hazard ratio (HR) for infection [1.26 (P = .39)], while obesity and smoking were associated with statistically significant HRs [2.02 (P = .02) and 2.20 (P < .01), respectively].

Conclusion: SLGT2i likely does not have a large effect on rates of IPP infection and may be continued perioperatively. Smoking cessation and weight loss may decrease the risk of IPP infections in diabetic patients, and counseling on this should be considered.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Urology
Urology 医学-泌尿学与肾脏学
CiteScore
3.30
自引率
9.50%
发文量
716
审稿时长
59 days
期刊介绍: Urology is a monthly, peer–reviewed journal primarily for urologists, residents, interns, nephrologists, and other specialists interested in urology The mission of Urology®, the "Gold Journal," is to provide practical, timely, and relevant clinical and basic science information to physicians and researchers practicing the art of urology worldwide. Urology® publishes original articles relating to adult and pediatric clinical urology as well as to clinical and basic science research. Topics in Urology® include pediatrics, surgical oncology, radiology, pathology, erectile dysfunction, infertility, incontinence, transplantation, endourology, andrology, female urology, reconstructive surgery, and medical oncology, as well as relevant basic science issues. Special features include rapid communication of important timely issues, surgeon''s workshops, interesting case reports, surgical techniques, clinical and basic science review articles, guest editorials, letters to the editor, book reviews, and historical articles in urology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信